RxDoctor Payments Data

Paetra Ruddy, MD

Dermatology · Poulsbo, WANPI 1366738874

Payments from drug & device makers

$5,605in general payments, 2019–2025

Across 282 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$1K
  • Amgen$729
  • Incyte Corporation$276
  • E.r. Squibb & Sons, L.L.C.$265
  • Lilly USA, LLC$257
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,04190%
  • Education$56410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,605 in reported general payments places this provider in the 75th percentile of 323 dermatology providers in Washington.

See all dermatology providers in Washington

Medicare billing

Part B allowed, 2024
$494,720
Medicare patients
1,493
Services billed
9,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab13$163,873
OtezlaApremilast22$147,633
Dupixent PenDupilumab21$78,831
Tacrolimus88$8,210
Clobetasol Propionate105$5,340
Calcipotriene41$4,756
Fluorouracil48$3,205
Pimecrolimus14$1,954
Metronidazole48$1,899
Ketoconazole107$1,634
Doxycycline Hyclate105$1,572
Tretinoin15$1,189
Ciclopirox30$1,073
Azelaic Acid13$814
Triamcinolone Acetonide85$754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,210$163,87313 claims
AmgenOtezla$729$147,63322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 dermatology providers in Washington.

Other dermatology in Poulsbo

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →